Conjunctivitis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CNJ013 MIFTS: 66	Conjunctivitis Categories: Eye diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Conjunctivitis

MalaCards integrated aliases for Conjunctivitis:

Name: Conjunctivitis ¹¹ ⁷⁵ ²⁸ ⁵³ ² ⁴³ ¹⁴ ⁶³ ¹⁶ ⁷¹ ³¹ ³³

Acute Adenoviral Follicular Conjunctivitis ³³

Inclusion Conjunctivitis of the Adult ³³

Swimming-Pool Conjunctivitis ³³

Inflammation of Conjunctiva ³³

Adenoviral Conjunctivitis ³³

Koch-Weeks Conjunctivitis ³³

Acute Conjunctivitis ³³

Catarrhal Ophthalmia ³³

Eye Catarrh ³³

Madras Eye ¹¹

Ophthalmia ³³

Classifications:

MalaCards categories:
Global: Infectious diseases Rare diseases
Anatomical: Eye diseases Neuronal diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Certain infectious and parasitic diseases

Other viral diseases

Viral conjunctivitis

Conjunctivitis due to adenovirus

Diseases of the eye and adnexa

Disorders of conjunctiva

Conjunctivitis

Conjunctivitis, unspecified

Disorders of conjunctiva in diseases classified elsewhere

Conjunctivitis in other diseases classified elsewhere

ICD11: ³³

Certain infectious or parasitic diseases

Certain other viral diseases

Viral conjunctivitis

Conjunctivitis due to adenovirus

Diseases of the visual system

Disorders of the eyeball - anterior segment

Disorders of conjunctiva

Conjunctivitis

Conjunctivitis, unspecified

Mucopurulent conjunctivitis

Conjunctivitis due to Koch-Weeks bacillus

Other specified conjunctivitis

External Ids:

Disease Ontology ¹¹ DOID:6195

ICD9CM ³⁴ 372.30

MeSH ⁴³ D003231

NCIt ⁴⁹ C34504

SNOMED-CT ⁶⁸ 193857008

ICD10 ³¹ B30.1 H10 H10.9 more

EFO ¹⁶ EFO_0009450

ICD11 ³³ 1094028194 447802965 831696556 more

UMLS ⁷¹ C0009763

Sources

Summaries for Conjunctivitis

PubMed Health : ⁶³ Conjunctivitis: Conjunctivitis, also known as pink eye, is an inflammation of the conjunctiva. The conjunctiva is a protective membrane covering the white part of the eye and the inner side of the eyelid. When people have conjunctivitis, both of their eyes are often red because the infection can spread very easily from one eye to the other. Conjunctivitis is most commonly caused by bacteria or viruses, and sometimes by an allergy. Bacterial conjunctivitis usually gets better within a week without treatment, but viral infections can last as long as four weeks. Because the virus can easily spread through contact with your fingers, it is important not to touch an infected eye with your bare hands. If you do touch your eye, be sure to wash your hands right away. It is also a good idea to use your own towels and washcloths, and not share them with other people.

MalaCards based summary: Conjunctivitis, also known as acute adenoviral follicular conjunctivitis, is related to giant papillary conjunctivitis and bacterial conjunctivitis, and has symptoms including bloodshot eye, conjunctival congestion and redness of eye. An important gene associated with Conjunctivitis is PLG (Plasminogen), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Pheniramine and Iodine have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and skin, and related phenotypes are homeostasis/metabolism and growth/size/body region

CDC: ² People often call conjunctivitis "pink eye" because it can cause the white of the eye to take on a pink or red color. Symptoms of pink eye can vary but typically include redness or swelling of the white of the eye.

Disease Ontology: ¹¹ A conjunctival disease characterized by an inflammation of the conjunctiva, the outermost layer of the eye and the inner surface of the eyelids.

Wikipedia: ⁷⁵ Conjunctivitis, also known as pink eye, is inflammation of the outermost layer of the white part of the... more...

Sources

Related Diseases for Conjunctivitis

Diseases in the Conjunctivitis family:

Acute Conjunctivitis	Chronic Conjunctivitis
Bacterial Conjunctivitis	Rare Conjunctivitis

Diseases related to Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1129)

#	Related Disease	Score	Top Affiliating Genes
1	giant papillary conjunctivitis	32.8	RNASE3 IL5 IL4 IL13 CXCL8 CCL11
2	bacterial conjunctivitis	32.7	TNF IL6 IL10 CXCL8
3	blepharoconjunctivitis	32.6	IL4 IL13
4	papillary conjunctivitis	32.5	RNASE3 IL5 IL4 IL13 CXCL8 CCL11
5	vernal conjunctivitis	32.3	IL4 CCL11
6	allergic conjunctivitis	32.1	TNF RNASE3 IL6 IL5 IL4 IL33
7	severe cutaneous adverse reaction	32.1	TNF IL6 IFNG
8	pollen allergy	31.9	IL5 IL4 IL13 IL10
9	tularemia	31.8	TNF TLR4 IL6
10	measles	31.8	TLR4 TLR3 IL6 IL2
11	graves ophthalmopathy	31.8	TNF IL6 IFNG ICAM1
12	chronic conjunctivitis	31.8	TNF RNASE3 IL6 IL5 IL4 IL33
13	periodic fever, familial, autosomal dominant	31.8	TNF NLRP3 IL6
14	avian influenza	31.7	TNF TLR3 IL6 IL10 CXCL8 CCL2
15	vernal keratoconjunctivitis	31.6	RNASE3 IL4 IL13 CCL11
16	allergic rhinitis	31.5	RNASE3 IL5 IL4 IL13 IL10 IGHE
17	trachoma	31.5	TNF IL6 IL4 IL10
18	trichinosis	31.5	TNF IL6 IL5 IL4 IL13 IL10
19	chronic rhinitis	31.4	RNASE3 IL5 IL4 IL33 IL13 HRH1
20	haemophilus influenzae	31.4	TNF CXCL8
21	keratoconjunctivitis	31.3	TNF RNASE3 IL5 IL4 IL2 IL13
22	panuveitis	31.3	TNF IL6 IL10 IFNG
23	keratitis, hereditary	31.3	TNF TLR4 NLRP3 IL6 IL10 CXCL8
24	chlamydia	31.3	TNF TLR4 IL6 IL5 IL4 IL10
25	rubella	31.2	TNF TLR4 TLR3 IL6 IL5 IL4
26	choroiditis	31.1	TNF IL10 IFNG
27	blepharitis	31.0	TNF IL6 IL4 IL2 IL13 CXCL8
28	urethritis	31.0	TNF TLR4 IL6 IL10 CXCL8
29	posterior uveitis	31.0	TNF IL6 IL5 IL2 IL13
30	corneal ulcer	30.9	TNF IL6 CCL11
31	dry eye syndrome	30.9	TNF IL6 IL10 ICAM1 CXCL8
32	bullous pemphigoid	30.8	TNF RNASE3 IL6 IL5 IL4 IGHE
33	endophthalmitis	30.8	TNF PLG IL6 ICAM1 CXCL8
34	eye disease	30.7	TNF TLR4 TLR3 PLG NLRP3 IL6
35	iritis	30.7	TNF IL6 IL10
36	cellulitis	30.7	TNF RNASE3 IL6 IL5 CXCL8
37	anterior uveitis	30.7	TNF TLR4 IL6 IL2 IL10 IFNG
38	scleritis	30.7	TNF IL5 IL4 IFNG CCL2
39	ige responsiveness, atopic	30.7	RNASE3 IL5 IL4 IL13 IL10 IGHE
40	neovascular glaucoma	30.6	PLG IL6 CXCL8 CCL2
41	spondyloarthropathy 1	30.6	TNF TLR4 IL6 IL10
42	pharyngitis	30.6	TNF NLRP3 IL6 CXCL8
43	exanthem	30.6	TNF NLRP3 IL6 IL4 IL2 IL10
44	dacryoadenitis	30.6	IL4 IL13 IL10
45	hypereosinophilic syndrome	30.6	RNASE3 IL5 IL4 IL2 IL13 IL10
46	endometritis	30.5	TNF TLR4 IL6 CXCL8
47	respiratory syncytial virus infectious disease	30.5	IL5 IL13
48	hydrocephalus	30.5	TNF TLR4 IL10 IFNG
49	rhinitis	30.5	TNF TLR4 RNASE3 IL6 IL5 IL4
50	hypopyon	30.5	TNF IL6 IL10

Comorbidity relations with Conjunctivitis via Phenotypic Disease Network (PDN): (show all 19)

Active Peptic Ulcer Disease	Acute Cystitis
Alzheimer Disease, Familial, 1	Blepharitis
Bronchitis	Decubitus Ulcer
Deficiency Anemia	Familial Atrial Fibrillation
Heart Disease	Hypertension, Essential
Hypothyroidism	Iron Deficiency Anemia
Osteoporosis	Parkinson Disease, Late-Onset
Protein-Energy Malnutrition	Respiratory Failure
Schizophreniform Disorder	Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Conjunctivitis:

Sources

Symptoms & Phenotypes for Conjunctivitis

UMLS symptoms related to Conjunctivitis:

bloodshot eye; conjunctival congestion; redness of eye; discharge from eye

MGI Mouse Phenotypes related to Conjunctivitis:

⁴⁵ (show all 19)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.44	CCL2 HRH1 ICAM1 IFNG IL10 IL13
2	growth/size/body region	MP:0005378	10.4	CCL2 HRH1 ICAM1 IFNG IL10 IL13
3	immune system	MP:0005387	10.39	CCL11 CCL2 HRH1 ICAM1 IFNG IGHE
4	nervous system	MP:0003631	10.38	CCL2 ICAM1 IFNG IL10 IL13 IL33
5	digestive/alimentary	MP:0005381	10.34	CCL2 ICAM1 IFNG IL10 IL13 IL2
6	liver/biliary system	MP:0005370	10.33	CCL2 HRH1 IFNG IL10 IL2 IL4
7	neoplasm	MP:0002006	10.32	CCL2 ICAM1 IFNG IL10 IL2 IL5
8	cellular	MP:0005384	10.29	CCL2 ICAM1 IFNG IL10 IL13 IL2
9	muscle	MP:0005369	10.26	CCL2 HRH1 ICAM1 IFNG IL10 IL13
10	endocrine/exocrine gland	MP:0005379	10.25	ICAM1 IFNG IL10 IL13 IL2 IL33
11	respiratory system	MP:0005388	10.22	CCL11 IFNG IL10 IL13 IL2 IL33
12	reproductive system	MP:0005389	10.21	CCL2 IFNG IL10 IL13 IL2 IL33
13	cardiovascular system	MP:0005385	10.2	CCL2 ICAM1 IFNG IL10 IL2 IL33
14	no phenotypic analysis	MP:0003012	10.18	IFNG IGHE IL10 IL13 IL2 IL33
15	hematopoietic system	MP:0005397	10.11	CCL11 CCL2 HRH1 ICAM1 IFNG IGHE
16	skeleton	MP:0005390	10.02	CCL2 IFNG IL10 IL13 IL33 IL4
17	vision/eye	MP:0005391	9.96	CCL2 ICAM1 IFNG IL10 IL2 IL4
18	mortality/aging	MP:0010768	9.83	CCL2 HRH1 ICAM1 IFNG IL10 IL13
19	integument	MP:0010771	9.36	CCL2 ICAM1 IFNG IL10 IL13 IL4

Sources

Drugs & Therapeutics for Conjunctivitis

PubMed Health treatment related to Conjunctivitis: ⁶³

Eye drops or ointments that contain antibiotics are often given as a treatment for conjunctivitis just in case it is a bacterial infection , even though conjunctivitis is more commonly caused by viruses . But antibiotics are only effective against bacteria , and have no effect on viruses. If the infection is viral, only the symptoms can be treated. Some people use non-antibiotic eye drops. Cold or warm compresses are also common. The effects of these treatments have not been properly studied, though. It is not clear if they are helpful, useless or possibly even harmful. If conjunctivitis is caused by an allergy , it can be treated with allergy medicine such as antihistamines .

Drugs for Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Pheniramine

Approved

Phase 4

86-21-5

4761

Iodine

Approved, Investigational

Phase 4

7553-56-2

807

Povidone-iodine

Approved

Phase 4

25655-41-8

Povidone K30

Approved, Experimental, Withdrawn

Phase 4

9003-39-8

6917 131751496

Loteprednol etabonate

Approved, Experimental

Phase 4

82034-46-6, 129260-79-3

22227703 9865442 444025

Ketotifen

Approved

Phase 4

34580-14-8, 34580-13-7

3827

Fluticasone

Approved, Experimental

Phase 4

90566-53-3

4659387 5311101

Alcaftadine

Approved

Phase 4

147084-10-4

19371515

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4

50-02-2

3003 5743

Tacrolimus

Approved, Investigational

Phase 4

104987-11-3

6473866 445643

Montelukast

Approved

Phase 4

158966-92-8

5281040

Dipivefrin

Approved

Phase 4

52365-63-6

3105

Moxifloxacin

Approved, Investigational

Phase 4

186826-86-8, 354812-41-2, 151096-09-2

152946

Estradiol

Approved, Investigational, Vet_approved

Phase 4

50-28-2

5757

Ethinylestradiol

Approved

Phase 4

57-63-6

5991

Polyestradiol phosphate

Approved

Phase 4

28014-46-2

Norgestimate

Approved, Investigational

Phase 4

35189-28-7

6540478

Tobramycin

Approved, Investigational

Phase 4

32986-56-4

36294

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Loratadine

Approved, Investigational

Phase 4

79794-75-5

3957

Emedastine

Approved

Phase 4

87233-61-2

3219

Desloratadine

Approved, Investigational

Phase 4

100643-71-8

124087

Polymyxin B

Approved, Vet_approved

Phase 4

1405-20-5, 1404-26-8

4868

Ganciclovir

Approved, Investigational

Phase 4

82410-32-0

3454

Racepinephrine

Approved, Vet_approved

Phase 4

51-43-4, 329-65-7

838 5816

Trimethoprim

Approved, Vet_approved

Phase 4

738-70-5

5578

Hyaluronic acid

Approved, Vet_approved

Phase 4

9004-61-9

53477741

Bepotastine

Approved

Phase 4

190786-44-8, 125602-71-3

2350 164522

Racephedrine

Approved, Experimental

Phase 4

299-42-3, 90-82-4, 90-81-3

5032 9294 7028

Phenylephrine

Approved

Phase 4

59-42-7

6041

Oxymetazoline

Approved, Investigational

Phase 4

1491-59-4

4636

Glutamic acid

Approved, Nutraceutical

Phase 4

56-86-0

33032

Maleic acid

Experimental, Investigational

Phase 4

110-16-7, 110-17-8

444266 444972

Cadexomer iodine

Experimental

Phase 4

94820-09-4

Tranilast

Investigational

Phase 4

53902-12-8

5282230

Spaglumic acid

Experimental

Phase 4

3106-85-2, 4910-46-7

188803 210320

Blood Substitutes

Phase 4

Anti-Infective Agents

Phase 4

Anti-Infective Agents, Local

Phase 4

Plasma Substitutes

Phase 4

Anti-Bacterial Agents

Phase 4

Antineoplastic Agents, Hormonal

Phase 4

Neuroprotective Agents

Phase 4

Hormones

Phase 4

Hormone Antagonists

Phase 4

Antiemetics

Phase 4

glucocorticoids

Phase 4

Gastrointestinal Agents

Phase 4

Interventional clinical trials:

(show top 50) (show all 374)

#	Name	Status	NCT ID	Phase	Drugs
1	To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™)	Unknown status	NCT01808768	Phase 4	Alcaftadine
2	Comparison of Tolerability Between Two Allergy Drops	Unknown status	NCT01390961	Phase 4	alacaftadine and naphazoline HCl & pheniramine maleate
3	Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses	Unknown status	NCT01337557	Phase 4	Bepotastine
4	Efficacy and Safety of LAIS® Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma	Unknown status	NCT02277483	Phase 4	LAIS®
5	Topical Tacrolimus in Vernal Keratoconjunctivitis	Unknown status	NCT02456025	Phase 4	Topical tacrolimus
6	A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%	Completed	NCT01437982	Phase 4	Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
7	A Comparison of Olopatadine Versus Fluticasone Nasal Spray in the Prevention of the Signs and Symptoms of Allergic Conjunctivitis	Completed	NCT00655109	Phase 4	Olopatadine;Fluticasone;Saline;Artificial tears
8	A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy	Completed	NCT02308501	Phase 4	Lastacaft ®;Tears Naturale ® (Placebo)
9	Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)	Completed	NCT00818805	Phase 4	Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
10	Mast-Cell Stabilizing Effects of Olopatadine	Completed	NCT00389025	Phase 4	Olopatadine (generic name)
11	Single Center, Randomized, Double-Masked Evaluation of the Efficacy of PredAcetate 1% Ophthalmic Suspension Compared to Pred Acetate 0.12% Ophthalmic Suspension, Lot Etab 0.2% Ophthalmic Suspension, and Placebo in a Modified CAC Model	Completed	NCT00689078	Phase 4	Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
12	Effectiveness of Olopatadine HCl Ophthalmic Solution, 0.1% Compared to Epinastine HCl Ophthalmic Solution, 0.05% in the Treatment of Allergic Conjunctivitis to Japanese Cedar Pollen	Completed	NCT02251613	Phase 4	Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
13	Montelukast as a Controller of Atopic Syndrome	Completed	NCT00559546	Phase 4	montelukast
14	DEXTENZA Versus Topical Steroid or Antihistamine Therapy for Treatment of Allergic Conjunctivitis	Completed	NCT04708821	Phase 4	Dexamethasone ophthalmic insert 0.4Mg;0.2% loteprednol etabonate ophthalmic suspension;olopatadine hydrochloride ophthalmic solution 0.7%
15	Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment	Completed	NCT00798577	Phase 4	Vigamox Ophthalmic Solution;BSS placebo
16	Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2%	Completed	NCT01697969	Phase 4	Olopatadine hydrochloride ophthalmic solution, 0.2%
17	A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model	Completed	NCT00534794	Phase 4	Elestat;Pataday
18	A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis	Completed	NCT00464438	Phase 4	gatifloxacin;moxifloxacin 0.5% eye drops
19	Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients	Completed	NCT01109485	Phase 4	Olopatadine hydrochloride ophthalmic solution 0.1%
20	A Randomized, Double-Masked, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of Maxidex® (0.1% Dexamethasone) Ophthalmic Suspension and Patanol® (0.1% Olopatadine Hydrochloride) Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model	Completed	NCT01119287	Phase 4	Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
21	A Single-Center, Randomized, Double-Masked, Parallel Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Reducing Ocular Itching in Subjects With Allergic Conjunctivitis	Completed	NCT05265910	Phase 4	olopatadine hydrochloride ophthalmic solution 0.7%;loratadine 10 mg;Tears Naturale;Placebo
22	Safety and Efficacy Comparison Ketotifen Ophthalmic Solution in Patients With Seasonal Allergic Conjunctivitis	Completed	NCT00133627	Phase 4	Ketotifen
23	Comparison of the Effect of Fluticasone Furoate Nasal Spray Versus Placebo on Allergic Mediators in the Tears of Subjects With Tree or Grass Pollen Allergy	Completed	NCT00891436	Phase 4	Fluticasone furoate nasal spray;Placebo nasal spray
24	A Single-Center, Randomized, Double-Masked, Parallel Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Reducing Ocular Itching in Subjects With Allergic Conjunctivitis	Completed	NCT05314621	Phase 4	olopatadine hydrochloride ophthalmic solution 0.7%);Fluticasone Propionate;Tears Naturale;Saline nasal spray
25	Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora	Completed	NCT00312338	Phase 4	VIGAMOX
26	A Double-blind, Placebo-controlled, Crossover, Single-center Study to Evaluate the Anti-allergic and Anti-inflammatory Effects of Multiple Doses of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms	Completed	NCT00311844	Phase 4	desloratadine
27	Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients	Completed	NCT01203540	Phase 4	NAABAK eyedrops;Saline eyedrops
28	Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis	Completed	NCT01569191	Phase 4	Anti-allergic Medication
29	The Effect of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer	Completed	NCT01346371	Phase 4	Refresh Tears 0.5% Lubricant Eye Drops;Bepreve 1.5% Ophthalmic Solution
30	A Study to Assess Alcon's Ocular Image Quantification Using Conjunctival Allergan Provocation Testing (CAPT) and Natural Allergen Exposure in an Environmental Exposure Chamber (EEC)	Completed	NCT01282138	Phase 4	Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
31	A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis	Completed	NCT01470118	Phase 4	alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
32	Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine	Completed	NCT01179412	Phase 4	2% povidone-iodine
33	Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis	Completed	NCT01159769	Phase 4	Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
34	Patient Perception Study for AL-4943A	Completed	NCT01294969	Phase 4	AL-4943A
35	A Multi-Site, Open-Label Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis	Completed	NCT01272089	Phase 4	Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
36	A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis	Completed	NCT01732757	Phase 4	Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
37	A Single-Center, Masked, Randomized Study Comparing Bepreve (Bepotastine Besilate) 1.5% - H1 Specific Antihistamine vs. Alrex (Loteprednol Etabonate) 0.2% - Corticosteroid in Subjects With Moderate to Severe Allergic Conjunctivitis	Completed	NCT01443442	Phase 4	bepotastine besilate, 1.5%;Loteprednol etabonate
38	A Single-Center, Randomized, Double-Masked, Placebo-Controlled Evaluation of the Efficacy of Flonase (Fluticasone Propionate Nasal Spray) Compared to Placebo Nasal Spray in the Allergen BioCube (ABC) Model	Completed	NCT01439815	Phase 4	Fluticasone Propionate Nasal Spray;Saline Nasal Spray
39	A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model	Completed	NCT01730872	Phase 4	Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
40	A Phase 4, Randomized, Double-Masked, Single Center, Placebo-Controlled Adaptive Clinical Trial, Using Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, in Subjects With Allergic Conjunctivitis to Evaluate a Modified Conjunctival Allergen Challenge (CAC) Model	Completed	NCT01534195	Phase 4	Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
41	A Phase IV, Open-label, Safety and Tolerability Trial of MK-3641 and MK-7243 Coadministered in Subjects At Least 18 Years of Age With Ragweed and Grass Pollen Induced Allergic Rhinitis With or Without Conjunctivitis	Completed	NCT02256553	Phase 4	Rescue Medication
42	A Single Blinded Clinical Trial Comparing Polytrim Ophthalmic Solution and Moxifloxacin Ophthalmic Solution for Treatment of Conjunctivitis.	Completed	NCT00581542	Phase 4	moxifloxacin;polytrim
43	A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Ganciclovir Gel (Zirgan®) Versus 0.3% Hypromellose Gel (Genteal Gel®; Placebo) for the Treatment of Adenovirus Conjunctivitis	Completed	NCT01533480	Phase 4	Zirgan;genteal gel
44	Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis	Completed	NCT00705159	Phase 4	loteprednol etabonate and tobramycin;loteprednol etabonate;Tobramycin;Vehicle of Zylet
45	Bilastine and Montelukast in Patients With Seasonal Allergic Rhinoconjunctivitis and Asthma: Efficacy of Concomitant Administration - the SKY Study	Completed	NCT02761252	Phase 4	Bilastine 20mg;Montelukast 10mg;Placebo Bilastine 20mg;Placebo Montelukast 10mg
46	A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Grasses Given With a Rush Induction Schedule to Patients With Allergic Rhinoconjunctivitis	Completed	NCT01059266	Phase 4	PURETHAL Grasses, 20.000 AUM/ml
47	Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis	Completed	NCT00357019	Phase 4	N-acetyl-aspartyl-glutamate (NAAXIA Sine)
48	Observational National Clinical Trial of Safety and Tolerance in Patients Suffering of an Allergic Grass Pollen Rhinitis and Treated by Grazax in Real Life Settings	Completed	NCT01433510	Phase 4	Grazax
49	Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial	Completed	NCT01211327	Phase 4	Cyclosporine A;Dexamethasone
50	A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis	Completed	NCT03464435	Phase 4	Tacrolimus

Search NIH Clinical Center for Conjunctivitis

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Cromolyn

Cromolyn Sodium

Oxymetazoline

Oxymetazoline hydrochloride

prednisolone

prednisolone acetate

PREDNISOLONE ACETATE PWDR

PREDNISOLONE PWDR

Prednisolone sodium phosphate

prednisolone tebutate

Cochrane evidence based reviews: conjunctivitis

Sources

Genetic Tests for Conjunctivitis

Genetic tests related to Conjunctivitis:

#	Genetic test	Affiliating Genes
1	Conjunctivitis ²⁸

Sources

Anatomical Context for Conjunctivitis

Organs/tissues related to Conjunctivitis:

MalaCards : Eye, Salivary Gland, Skin, T Cells, Thymus, Bone Marrow, Lymph Node

Sources

Publications for Conjunctivitis

Articles related to Conjunctivitis:

(show top 50) (show all 14170)

#	Title	Authors	PMID	Year
1	[Lacrimal assessment of lg E in cases with allergic conjunctivitis]. ⁵³ ⁶²	Turlea M...Turlea C	20361659	2009
2	Traffic-related outdoor air pollution and respiratory symptoms in children: the impact of adjustment for exposure measurement error. ⁵³ ⁶²	Van Roosbroeck S...Spiegelman D	18379431	2008
3	IgE antibody on worn highly oxygen-permeable silicone hydrogel contact lenses from patients with contact lens-induced papillary conjunctivitis (CLPC). ⁵³ ⁶²	Zhao Z...Willcox MD	18327049	2008
4	[Tumor necrosis factor receptor associated periodic syndrome (TRAPS). Report of two cases]. ⁵³ ⁶²	Alvarez-Lobos M...Yague J	17277873	2006
5	[Tear eosinophil cationic protein measurement in patients with seasonal allergic conjunctivitis]. ⁵³ ⁶²	Muromoto K...Kato H	16491868	2006
6	Periodic fever, mild arthralgias, and reversible moderate and severe organ inflammation associated with the V198M mutation in the CIAS1 gene in three German patients--expanding phenotype of CIAS1 related autoinflammatory syndrome. ⁵³ ⁶²	Porksen G...Roesler J	15245511	2004
7	The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. ⁵³ ⁶²	Aksentijevich I...Kastner DL	11443543	2001
8	Correlation between tear IgE levels and HLA-DR expression by conjunctival cells in allergic and nonallergic chronic conjunctivitis. ⁵³ ⁶²	Baudouin C...Goguel A	11148813	2000
9	Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens. ⁵³ ⁶²	Aghayan-Ugurluoglu R...Valenta R	10756233	2000
10	Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. ⁵³ ⁶²	Valenta R...Stingl G	9856836	1998
11	Eosinophil granule proteins expressed in ocular cicatricial pemphigoid. ⁵³ ⁶²	Heiligenhaus A...Steuhl KP	9602632	1998
12	[Value of lacrymal IgE determination and conjunctival cytology in the diagnosis of chronic conjunctivitis]. ⁵³ ⁶²	Bourcier T...Baudouin C	9759406	1998
13	Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure. ⁵³ ⁶²	Tomassini M...Bonini S	8648032	1996
14	Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis. ⁵³ ⁶²	Noble S...McTavish D	8612470	1995
15	Ligneous Conjunctivitis Secondary to Viral Conjunctivitis. ⁶²	Quintero-Estades JA...Perry HD	36459582	2023
16	The effect of topical steroids and non-steroidal anti inflammatory drugs on epiphora of unknown cause: Optical Coherence Tomography Study. ⁶²	Ceylanoglu KS...Sen EM	36470407	2022
17	Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials. ⁶²	Simpson EL...Wollenberg A	36082590	2022
18	Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicentre retrospective cohort in daily practice. ⁶²	Lasek A...Research Group of eczema atopique (GREAT)	35854650	2022
19	Delineating septo-optic dysplasia. ⁶²	Lubinsky M...Encha-Razavi F	36200678	2022
20	Demographic profile of patients seeking teleophthalmology consultations through e-Sanjeevani: Retrospective analysis of 5138 patients from North India. ⁶²	Markan A...Singh M	36453323	2022
21	Papillary conjunctivitis presenting months after permanent eyebrow tattooing. ⁶²	Gaspari M...Chaudhry IM	36407011	2022
22	Updates of ocular involvement in granulomatosis with polyangiitis. ⁶²	Mei L...Yan H	36473987	2022
23	Monkeypox as an emerging infectious disease: the ophthalmic implications. ⁶²	Milligan AL...Dunning J	36216412	2022
24	Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials. ⁶²	Takamizawa S...Suzuki S	36471215	2022
25	Outpatient human coronavirus associated conjunctivitis in India. ⁶²	Prajna NV...Doan T	36209621	2022
26	Similarities and differences between MIS-C and KD: a systematic review and meta-analysis. ⁶²	Tong T...Gong F	36471327	2022
27	Accuracy of the International Classification of Diseases, 9th Revision for Identifying Infantile Eye Disease. ⁶²	Xu TT...Mohney BG	34821545	2022
28	Deep sequencing analysis of clinical samples from patients with acute infectious conjunctivitis during the COVID-19 delta surge in Madurai, India. ⁶²	Lalitha P...Seitzman GD	36242841	2022
29	Conjunctivitis associated with capecitabine treatment in a patient with colon cancer: The importance on educating patients into identifying adverse reactions. ⁶²	Bello Crespo M...Gioseffi HA	35369809	2022
30	A survey of allergic conjunctivitis in children in China. ⁶²	Gao X...Xiang Q	36470950	2022
31	Efficacy of Proactive Topical Antihistamine Use in Patients with Seasonal Allergic Conjunctivitis. ⁶²	Fukushima A...Proactive Study Group	36244054	2022
32	Severe Acute Respiratory Syndrome Coronavirus 2-Associated Blepharoconjunctivitis and Erythema Multiforme-Like Rash in a Young Man. ⁶²	Fernandez KB...Mercer RN	36198619	2022
33	Signs and symptoms of COVID-19 in patients with multiple sclerosis. ⁶²	Schiavetti I...MuSC-19 Study Group	36086905	2022
34	The effect of thermo-mechanical device (Tixel) treatment on evaporative dry eye disease - A pilot prospective clinical trial. ⁶²	Safir M...Hartstein ME	35864019	2022
35	Concurrent pigeon paramyxovirus-1 and Acinetobacter baumannii infection in a fatal case of pneumonia. ⁶²	Zou X...Cao B	35290154	2022
36	Differential expression of long non-coding RNAs under Peste des petits ruminants virus (PPRV) infection in goats. ⁶²	Pandey A...Gandham RK	35129076	2022
37	Multimodal imaging in the diagnosis and management of ophthalmia nodosa. ⁶²	Ashkenazy N...Davis JL	36324631	2022
38	Associations between conjunctivitis and ambient PM2.5 and physical activity: A nationwide prospective cohort study. ⁶²	Chen G...Zhang Z	35981585	2022
39	[First- and second-line hospital management of ophthalmologic emergencies: Clinical pathway study of 1360 patients]. ⁶²	Dos Santos LM...Henry A	36470749	2022
40	Spectrum and resistance in bacterial infections of the ocular surface in a German tertiary referral center 2009-2019. ⁶²	Roth M...Geerling G	35687174	2022
41	Ocular Injuries Related to Grooming Visits in Dogs: 161 Cases (2004-2020). ⁶²	Chmiel J...Rozanski E	36315866	2022
42	High-Resolution Imaging of the Ocular Vasculature of Conjunctivitis in Mice Using Highly Bright Polymer Dots. ⁶²	Li Y...Xiong L	36027786	2022
43	What Signs and Symptoms Are Suggestive of Bacterial Conjunctivitis? ⁶²	Gottlieb M...Davis TE	36334957	2022
44	Distribution and genetic diversity of Feline calicivirus in Moscow metropolitan area. ⁶²	Komina A...Gulyukin A	36448438	2022
45	In Vitro efficacy of cyclosporine a and various antiseptics and antiviral drugs on adenovirus genotype 8, a common cause of epidemic keratoconjunctivitis. ⁶²	Aydamirov AS...Yagmur M	36346478	2022
46	Ocular Side Effects of Bisphosphonates: A Review of Literature. ⁶²	Chartrand NA...Moshirfar M	36409537	2022
47	Pathogenicity of a novel classical swine fever LOM vaccine-derived virus isolated on Jeju Island, South Korea. ⁶²	Jang G...Lee C	35944180	2022
48	Differential symptomology of possible and confirmed Ebola virus disease infection in the Democratic Republic of the Congo: a retrospective cohort study. ⁶²	Nsio J...Ahuka-Mundeke S	36370717	2022
49	Hyper-Reflective Outer Nuclear Layer (HONL) in Vogt-Koyanagi-Harada Disease and Sympathetic Ophthalmia. ⁶²	Fonollosa A...Agarwal A	36332138	2022
50	Occurrence of Chlamydia spp. in Conjunctival Samples of Stray Cats in Timișoara Municipality, Western Romania. ⁶²	Tirziu A...Degi J	36363779	2022

Sources

Genes for Conjunctivitis

Genes related to Conjunctivitis (0 elite genes):

(show all 39)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	PLG	Plasminogen	Protein Coding	23.16	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
2	NLRP3	NLR Family Pyrin Domain Containing 3	Protein Coding	21.85	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders (show sections)	15245511
3	RNASE3	Ribonuclease A Family Member 3	Protein Coding	19.63	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8648032 16491868 9602632
4	HRH1	Histamine Receptor H1	Protein Coding	18.18	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8612470
5	IL4	Interleukin 4	Protein Coding	15.77	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
6	IL13	Interleukin 13	Protein Coding	15.47	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
7	IGHE	Immunoglobulin Heavy Constant Epsilon	Protein Coding	15.27	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	20361659 18327049 10756233 (more) 11148813 9759406
8	IL5	Interleukin 5	Protein Coding	15.08	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	IL6	Interleukin 6	Protein Coding	15.03	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	TNF	Tumor Necrosis Factor	Protein Coding	14.81	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	14.7	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	IL10	Interleukin 10	Protein Coding	14.51	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	CCL11	C-C Motif Chemokine Ligand 11	Protein Coding	14.5	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	IL2	Interleukin 2	Protein Coding	14.31	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	IFNG	Interferon Gamma	Protein Coding	14.11	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	ICAM1	Intercellular Adhesion Molecule 1	Protein Coding	13.84	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	TLR4	Toll Like Receptor 4	Protein Coding	13.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	CCL2	C-C Motif Chemokine Ligand 2	Protein Coding	13.48	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	IL33	Interleukin 33	Protein Coding	13.41	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	TLR3	Toll Like Receptor 3	Protein Coding	12.97	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	IL7	Interleukin 7	Protein Coding	12.93	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
22	MMP9	Matrix Metallopeptidase 9	Protein Coding	12.9	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
23	MEFV	MEFV Innate Immunity Regulator, Pyrin	Protein Coding	12.86	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	FOXP3	Forkhead Box P3	Protein Coding	12.8	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	HLA-B	Major Histocompatibility Complex, Class I, B	Protein Coding	12.68	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
26	CCL24	C-C Motif Chemokine Ligand 24	Protein Coding	12.65	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
27	CXCL9	C-X-C Motif Chemokine Ligand 9	Protein Coding	12.61	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	12.45	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	PTGDR2	Prostaglandin D2 Receptor 2	Protein Coding	12.42	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
30	MPO	Myeloperoxidase	Protein Coding	12.39	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
31	NLRP12	NLR Family Pyrin Domain Containing 12	Protein Coding	12.29	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
32	NLRC4	NLR Family CARD Domain Containing 4	Protein Coding	12.22	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
33	IL1RL1	Interleukin 1 Receptor Like 1	Protein Coding	11.88	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
34	BTK	Bruton Tyrosine Kinase	Protein Coding	11.81	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
35	EPX	Eosinophil Peroxidase	Protein Coding	11.79	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
36	IL16	Interleukin 16	Protein Coding	11.77	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
37	LTF	Lactotransferrin	Protein Coding	11.72	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
38	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	11.67	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
39	SOCS5	Suppressor Of Cytokine Signaling 5	Protein Coding	11.66	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Conjunctivitis

Sources

Expression for Conjunctivitis

Search GEO for disease gene expression data for Conjunctivitis.

Sources

Pathways for Conjunctivitis

Pathways related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 89)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	14.04	CCL11 CCL2 CXCL8 ICAM1 IFNG IL10
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.92	CCL11 CCL2 CXCL8 IL10 IL13 IL2
3	Signal Transduction ⁶⁶	13.86	TNF PLG IL6 IL5 IL33 IL2
4	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.77	TNF TLR4 IL6 IL5 IL4 IL33
5	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.68	TNF IL6 IL5 IL4 IL2 IL13
6	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.57	CCL11 CCL2 CXCL8 IL10 IL13 IL2
7	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.44	TNF IL6 IL5 IL4 IL2 IL13
8	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.44	TNF IL6 IL5 IL4 IL33 IL2
9	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.95	TNF TLR4 TLR3 IL6 IL2 CXCL8
10	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.81	TNF IL6 IL5 IL4 IL2 IL13
11	NF-KappaB Family Pathway ⁶⁴ Show member pathways NF-KappaB (p50-p65) Pathway ⁶⁴	12.78	TNF TLR4 TLR3 IL6 IL2
12	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.76	TNF PLG IL6 IL2 IL10 IFNG
13	NF-kappaB Signaling ³	12.74	TNF TLR3 IL4 IL2 IL10 IFNG
14	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.68	CXCL8 IL6 NLRP3 TLR3 TLR4 TNF
15	Bacterial infections in CF airways ²² Show member pathways Altered glycosylation of MUC1 in tumor microenvironment ⁷⁴ IL-1 beta-dependent CFTR expression ²² IL1-mediated signaling events ⁶¹ Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²² NTHi-Induced Signaling ⁶⁴ Signal transduction through IL1R ⁷⁴	12.61	TNF TLR4 IL6 IL4 IFNG CXCL8
16	DDX58/IFIH1-mediated induction of interferon-alpha/beta ⁶⁶ Show member pathways Immune response TLR3 and TLR4 induce TICAM1-specific signaling pathway ²² Negative regulators of DDX58/IFIH1 signaling ⁶⁶ NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 ⁶⁶ Novel intracellular components of RIG-I-like receptor pathway ⁷⁴ SARS-CoV-2 B.1.1.7 variant antagonises innate immune activation ⁷⁴ TRAF3-dependent IRF activation pathway ⁶⁶ TRAF6 mediated IRF7 activation ⁶⁶	12.5	TLR4 TLR3 IFNG CXCL8
17	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.48	TNF TLR4 TLR3 IL6 IFNG CXCL8
18	IL-17 Family Signaling Pathways ⁶⁵ Show member pathways IL17 signaling pathway ⁶⁷ IL-17 signaling pathway ⁷⁴ Mucin expression in CF via IL-6, IL-17 signaling pathways ²²	12.35	TNF IL6 CXCL8 CCL2
19	Colorectal Cancer Metastasis ⁶⁴	12.34	TNF TLR4 TLR3 IL6 IFNG
20	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.33	IFNG IL10 IL2 IL4 IL5 TNF
21	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	12.32	CXCL8 IL10 IL13 IL6 TNF
22	Neuroinflammation and glutamatergic signaling ⁷⁴	12.29	TNF IL6 IL4 IL13 IL10 IFNG
23	Immune response CD16 signaling in NK cells ²² Show member pathways Immune response Role of DAP12 receptors in NK cells ²²	12.28	TNF IL4 IL2 IFNG
24	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	12.21	TNF IL6 IL5 IL4 IL2 IL10
25	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	12.19	TLR4 TLR3 IL5 IL2 IL13
26	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	12.12	TNF TLR4 TLR3 IL6 IL2 IL10
27	Allograft rejection ⁷⁴	12.08	CXCL8 IFNG IL10 IL13 IL2 IL4
28	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	12.05	TLR4 TLR3 IL6 IL4 IFNG
29	CCL18 signaling pathway ⁷⁴	12.02	IL6 IL10 CXCL8 CCL2
30	Cytokine production by Th17 cells in CF (Mouse model) ²² Show member pathways Cytokine production by Th17 cells in CF ²²	12.01	TLR4 IL6 ICAM1 CXCL8
31	Innate Lymphoid Cells Differentiation ⁶⁵	12	TNF IL5 IL4 IL33 IL2 IL13
32	Burn wound healing ⁷⁴	11.99	TNF TLR4 IL6 ICAM1 CXCL8 CCL2
33	Acute viral myocarditis ⁷⁴	11.98	TLR4 TLR3 IL6 IL2 IL10 IFNG
34	Glucocorticoid receptor regulatory network ⁶¹	11.97	IL6 IL5 IL4 IL2 IL13 IFNG
35	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.95	TNF IL6 IL2 IL10 IFNG
36	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.94	CCL11 CCL2 CXCL8 ICAM1 IL10 IL13
37	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ⁶¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ⁶¹	11.93	CXCL8 IFNG IL2 IL4 IL5 TNF
38	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.93	TNF TLR4 IL6 IL4 IL2 IL10
39	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.92	IL6 IGHE CXCL8 CCL2
40	Corticotropin-releasing hormone signaling pathway ⁷⁴	11.9	TLR4 IL2 CXCL8
41	AP-1 transcription factor network ⁶¹	11.9	CCL2 CXCL8 IFNG IL10 IL2 IL4
42	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.89	TNF IL6 IL2 IFNG ICAM1 CXCL8
43	miRNAs involvement in the immune response in sepsis ⁷⁴	11.88	TNF TLR4 IL6 IL10 ICAM1 CXCL8
44	Th17 cell differentiation pathway ⁷⁴	11.87	IL6 IL4 IL2 IFNG
45	Spinal cord injury ⁷⁴	11.87	CCL2 CXCL8 ICAM1 IFNG IL2 IL4
46	Activation of NF-KappaB by PKR ⁶⁴ Show member pathways Canonical NF-kB pathway ⁷⁴ Cellular Transformation by HTLV1 ⁶⁴ Inhibition of PKR ⁶⁶ STING pathway in Kawasaki-like disease and COVID-19 ⁷⁴	11.84	TNF NLRP3 IFNG
47	Lung fibrosis ⁷⁴	11.83	CCL11 CCL2 CXCL8 IL13 IL4 IL5
48	IL 10 signaling pathway ⁶⁷	11.82	TNF TLR4 IL6 IL10
49	IL4-mediated signaling events ⁶¹	11.8	IL5 IL4 IL10 CCL11
50	Interleukin-6 family signaling ⁶⁶ Show member pathways IL-6-type cytokine receptor ligand interactions ⁶⁶ Immune response Oncostatin M signaling via JAK-Stat in human cells ²² Interleukin-6 signaling ⁶⁶	11.79	IL6 CCL2 CCL11

Sources

GO Terms for Conjunctivitis

Cellular components related to Conjunctivitis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	10.15	CCL11 CCL2 CXCL8 IFNG IGHE IL10
2	extracellular space	GO:0005615	9.85	CCL11 CCL2 CXCL8 ICAM1 IFNG IGHE

Biological processes related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 72)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription by RNA polymerase II	GO:0045944	10.67	TNF TLR4 TLR3 NLRP3 IL6 IL4
2	positive regulation of gene expression	GO:0010628	10.48	CXCL8 IFNG IL13 IL33 IL4 IL6
3	signal transduction	GO:0007165	10.46	TNF TLR4 TLR3 NLRP3 IL6 IL5
4	positive regulation of ERK1 and ERK2 cascade	GO:0070374	10.41	TNF TLR4 ICAM1 CCL2 CCL11
5	defense response to virus	GO:0051607	10.37	IFNG IL33 IL6 NLRP3 TLR3
6	chemotaxis	GO:0006935	10.35	RNASE3 CXCL8 CCL2 CCL11
7	defense response to bacterium	GO:0042742	10.33	TNF TLR4 TLR3 RNASE3 IL10 IGHE
8	positive regulation of DNA-binding transcription factor activity	GO:0051091	10.32	TNF IL6 IL5 IL10
9	positive regulation of tumor necrosis factor production	GO:0032760	10.3	TLR4 TLR3 IL6 IL33 IFNG
10	cellular response to type II interferon	GO:0071346	10.29	TNF TLR4 TLR3 CCL2 CCL11
11	cellular response to lipopolysaccharide	GO:0071222	10.29	CCL2 CXCL8 IL10 IL6 NLRP3 TLR4
12	positive regulation of type II interferon production	GO:0032729	10.28	TNF TLR4 TLR3 IL2
13	negative regulation of inflammatory response	GO:0050728	10.28	IL10 IL13 IL2 IL4 NLRP3
14	defense response to Gram-positive bacterium	GO:0050830	10.27	TNF RNASE3 NLRP3 IL6
15	cellular response to mechanical stimulus	GO:0071260	10.27	TLR4 TLR3 IL33 IL13
16	positive regulation of NF-kappaB transcription factor activity	GO:0051092	10.27	TNF TLR4 TLR3 NLRP3 IL6
17	positive regulation of interleukin-6 production	GO:0032755	10.27	TNF TLR4 TLR3 IL6 IL33 IFNG
18	response to virus	GO:0009615	10.26	TNF TLR3 IFNG CCL11
19	positive regulation of interleukin-8 production	GO:0032757	10.26	TNF TLR4 TLR3 IL6
20	humoral immune response	GO:0006959	10.26	TNF IL6 IFNG CCL2
21	positive regulation of interleukin-1 beta production	GO:0032731	10.26	TNF TLR4 NLRP3 IL6 IFNG
22	positive regulation of smooth muscle cell proliferation	GO:0048661	10.24	TNF TLR4 IL6 IL13
23	extrinsic apoptotic signaling pathway	GO:0097191	10.24	TNF TLR3 IL33 IFNG
24	cellular response to virus	GO:0098586	10.23	TLR3 NLRP3 IL6 IFNG
25	regulation of insulin secretion	GO:0050796	10.22	TNF IL6 IFNG
26	response to activity	GO:0014823	10.22	TNF IL6 IL10
27	monocyte chemotaxis	GO:0002548	10.22	IL6 CCL2 CCL11
28	positive regulation of interleukin-10 production	GO:0032733	10.22	TLR4 IL6 IL4 IL13
29	positive regulation of cytokine production	GO:0001819	10.22	IFNG IL10 IL33 TLR3 TNF
30	cellular response to amyloid-beta	GO:1904646	10.21	TNF TLR4 ICAM1
31	negative regulation of type II interferon production	GO:0032689	10.21	TLR4 IL33 IL10
32	positive regulation of interleukin-12 production	GO:0032735	10.21	IFNG TLR3 TLR4
33	positive regulation of B cell proliferation	GO:0030890	10.21	TLR4 IL5 IL4 IL2 IL13
34	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	10.21	IFNG IL13 IL2 IL4 IL6 TNF
35	positive regulation of nitric oxide biosynthetic process	GO:0045429	10.2	TNF TLR4 IFNG
36	lipopolysaccharide-mediated signaling pathway	GO:0031663	10.2	CCL2 TLR4 TNF
37	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	10.2	IL10 IL5 IL6 TNF
38	negative regulation of endothelial cell apoptotic process	GO:2000352	10.19	IL4 IL13 IL10 ICAM1
39	liver regeneration	GO:0097421	10.18	IL10 IL6 TNF
40	negative regulation of osteoclast differentiation	GO:0045671	10.18	TLR4 TLR3 IL4
41	positive regulation of inflammatory response	GO:0050729	10.18	TNF TLR4 TLR3 NLRP3 IL33 IL2
42	positive regulation of cytokine production involved in inflammatory response	GO:1900017	10.17	TNF TLR4 IL6
43	negative regulation of neurogenesis	GO:0050768	10.16	CCL11 IL6 TNF
44	macrophage activation	GO:0042116	10.15	IL13 IL4 TLR4
45	positive regulation of macrophage activation	GO:0043032	10.15	TLR4 IL33 IL13 IL10
46	eosinophil chemotaxis	GO:0048245	10.14	HRH1 CCL2 CCL11
47	positive regulation of nitric-oxide synthase biosynthetic process	GO:0051770	10.14	TLR4 IL33 IFNG CCL2
48	positive regulation of neuroinflammatory response	GO:0150078	10.1	TNF IL6 IL33
49	microglial cell activation	GO:0001774	10.1	TNF TLR3 IL4 IL13 IFNG
50	positive regulation of chemokine production	GO:0032722	10.1	IFNG IL33 IL6 TLR3 TLR4 TNF